Inhibrx Biosciences (INBX) is a pre-revenue clinical-stage biopharmaceutical company with no commercial products, no inventory, no goodwill, and no intangible assets on its balance sheet. Under a liquidation lens, the asset base is dominated by cash and cash equivalents of $161.7 million as of March 31, 2026, which receives a 100% recovery haircut and is the near-entirety of realizable value. Property and equipment net of accumulated depreciation stood at $3.2 million (gross $14.9 million, accumulated depreciation $11.7 million); applying a 50-70% recovery haircut yields approximately $1.6-2.2 million. Prepaid expenses of $9.5 million have minimal liquidation value as the majority represent prepayments to CROs and CDMOs for clinical services with no third-party market. The operating lease right-of-use asset is offset by a corresponding lease liability of $5.9 million total ($2.4 million current, $3.5 million non-current), which does not extinguish on windup. On the liability side, the dominant obligation is the Amended 2025 Loan Agreement with Oxford Finance: face value principal of $190.75 million ($109.0 million Term A, $81.75 million Term B including the 9% final payment fee), maturing January 2030, with interest-only through February 2028. The March 2026 Amendment added $75.0 million in gross proceeds, increasing total face-value debt obligations materially from the prior period ($100.0 million principal at December 31, 2025). A minimum liquidity covenant of $40.0 million is tested at all times. Additional obligations include $15.3 million in accrued expenses, $5.9 million in operating lease liability, and approximately $15.8 million in noncancellable CDMO purchase commitments disclosed in MD&A but not separately XBRL-tagged. Liquidation math: cash ($161.7M) plus PP&E haircut (~$1.9M) minus face-value debt ($190.75M principal plus 9% final fee already embedded) minus accrued liabilities ($15.3M) minus operating lease ($5.9M) minus noncancellable purchase commitments (~$15.8M) yields a deeply negative recovery to equity, consistent with MFFAIS CLV of approximately negative $20.7 million before considering the noncancellable commitments and prepayment penalties (2-5% of principal). The prior filing (10-K, December 31, 2025) showed $100.0 million in outstanding principal; this filing reflects a $75.0 million incremental draw, materially worsening the recovery posture. Cash increased from approximately $124.3 million at year-end 2025 to $161.7 million post-draw. The net effect is a larger debt overhang relative to liquid assets. No goodwill, no separately capitalized intangibles, no inventory, and no receivables of note are present. The filing does not separately XBRL-tag the $15.8 million noncancellable CDMO purchase commitment; it is disclosed only in MD&A narrative.
▼ Community Notes